pramipexole has been researched along with cerivastatin in 1 studies
| Studies (pramipexole) | Trials (pramipexole) | Recent Studies (post-2010) (pramipexole) | Studies (cerivastatin) | Trials (cerivastatin) | Recent Studies (post-2010) (cerivastatin) |
|---|---|---|---|---|---|
| 1,103 | 219 | 517 | 556 | 91 | 46 |
| Protein | Taxonomy | pramipexole (IC50) | cerivastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.005 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0001 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0001 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0056 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
1 other study(ies) available for pramipexole and cerivastatin
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |